Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
Following the publication of the long-term mortality findings of the SAGhE consortium, we discuss the safety profile of growth hormone with consortium member Stefano Cianfarani.
Childhood cancer survivors and endocrinopathies – the need for oncologist and endocrinologist collaboration
Dr Sogol Mostoufi focuses on the treatment-related endocrine side effects commonly experienced by childhood cancer survivors, and the need for screening, life-long follow-up and treatment in this high-risk population.
Research focus: ‘Health not height’ – Trial results for a targeted treatment for children with achondroplasia
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosoritide in children with achondroplasia.
In this podcast, Dr Shylaja Srinivasan discusses the care of children and adolescents with type 2 diabetes, and how the findings of the TODAY2 and Ellipse trials will inform treatment decisions.
In our first edition, Professor Frederic Castinetti discussing the results of an international collaboration to study the natural history and treatment outcomes of multiple endocrine neoplasia type 2B, and Professor Martin Savage comments on a randomized trial of letrozole versus testosterone in boys with constitutional delay of growth and puberty.